Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2007-11-06
2010-11-30
Belyavskyi, Michail A (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
Reexamination Certificate
active
07842501
ABSTRACT:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.
REFERENCES:
patent: 5614611 (1997-03-01), Chang
patent: 5645837 (1997-07-01), Jameson et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5827737 (1998-10-01), Peterson et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6228621 (2001-05-01), Williams et al.
patent: 0814838 (2003-05-01), None
patent: WO 94/02156 (1994-02-01), None
patent: WO 00/23053 (2000-04-01), None
patent: WO 0023053 (2000-04-01), None
patent: WO 00/25722 (2000-05-01), None
patent: WO 0025722 (2000-05-01), None
Albert et al., “Dendritic Cells Acquire Antigen form Apoptotic Cells and Induce Class I-Restricted CTLs”, Nature, 1998, 392: pp. 86-89.
Alderson, M.R., et al. 1990. J. Exp. Med. 172:577-587.
Alters, et. al, Immunotherapy of cancer: Generation of CEA specific CTL using CEA peptide pulsed dendritic cells, Dendritic cells in Fundamental and Clinical Immunology, 1997, 417, 519-524.
Angelichio et al NAR 19(18):5037-5043 1991.
Bakker, et al., “Melancocyte-Lineage-specific Antigen gp100 is Recognized by Melanoma-Derived tumor-Infiltrating Lymphocytes”, J. Exp. Med. (1994) 179(3):1005-1009.
Bellone et al, Eur. J. Immunology 24:pp. 2691-2698, 1994.
Cai, et al, “Influence of Antigen Dose and Costimulation on the Primary Response of CD8* T Cells in Vitro,” J. Exp. Med. 1996, 183, 2247-2257.
Cai et al “Probing the activation requirements for naïve CD8* T cells with Drosophilia cell transfectants an antigen presenting cell,” Immunological Reviews, 1998, 165, 249-265.
Cai, et al, “Requirements for Peptide-induced T Cell Receptor Down regulation on Naïve CD8* cells,” J. Exp. Med., 1997, 185(4), 641-651.
Cai et al.,Transfected Drosophila as a Probe for Defining the Minimal Requirments for Stimulating Unprimed CD8+ T CellP.N. A.S. USA (1996) 93(25):14736-14741.
Chen et al., “Costimulation of T Cells for Tumor Immunity”, Imm. Today, vol. 14, No. 10: 1993, pp. 483-485.
de Waal Malefyl et al., Eur. J. Immunol., 1993, 23: 418-424.
Flesch et al, “Monocyte iinflammatory protein-I alpha facilities priming of CD8+T cells responses to exogenous viral antigen,” Int. Immunol, 2000, 12(9), 1365-1370.
Gagliardi, et al, “Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro,” Int. Immunol. 1995, 7(11), 1741-1752.
Godeau et al., “Expression of a mouse class I MHC molecule in insect cells using a baculovirus vector”, Journal of Cell Biology, 107(): Abstract #2092, 1988.
Grewal et al., “CD40 and CD154 in Cell-Mediated Immunity”, Annual Reviews in Immunology. vol. 16, 1998, pp. 111-135.
Goldsby et al, Immun. 5th Ed., Freeman and Company, New York, 2003, pp. 9-21 and 362-365.
Guelly C., et al ‘Activation Requirements of Circulating Antigen-Specific Human CD8+ Memory T Cells Probed with Insect Cell-Based Artificial Antigen-Presenting Cells’ Eur.J.Immunol. vol. 32, Jan. 2002, pp. 182-192.
Ho et al, “Journal of Clinical Investigation” (2002) 110(10): 1415-1417.
Hortsch, M. et al. TIBS, Aug. 1991, pp. 283-287.
Huang, J. et al, “TCR-mediated internatlization of peptide-MHC complexes acquired by T cells,” Science, Oct. 1999, 286(5441), 952-954.
Hwang, I. et. al., “T-cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived frm antigen-presenting cells,” Jurnal of Exp. Medicine, Apr. 3, 2000,191(7), 1137-1148.
Jackson et al,Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells, Proceedings of the Naitonal Academy of Sciences USA 89:12117-12121 1992.
Kawakami et al., “Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo tumor Regression,” J. Immunol. (1995) 154(8):3961-3968.
Lanzavecchia , A. Nature, vol. 393:1998, pp. 413-414.
Latouche, et. al., Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells, Nature Biotechnology, vol. 18, pp. 405-409, 2000.
Lustgarten et al., Eur. J. Immunol., vol. 25, 1995, pp. 2985-2991.
Luxembourg et al., Natur Biotechnology, vol. 16, 1998, pp. 281-285.
Mackensen A. et al ‘Phase I Study in Melanoma Patients of a Vaccine with Peptide-Pulseddendritic Cells Generated In Vitro from CD34+ Hematopoietic Progenitor Cells’ International Journal of Cancer, vol. 86, May 2000 pp. 385-392.
Matsumura et al.,In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells, Journal of Biological Chemistry 267(33):23589-23595 1992.
Miescher, S. et al, Cancer Res. 1988, 48: pp. 6992-6998.
Mitchell, M. et al ‘Phase I Trial of Adoptive Immunotherapy with Cytolytic T Lymphocytes Immunized Against a Tryosinase Epitope’ Journal of Clinical Oncology, vol. 20, No. 4, Feb. 2002, pp. 1075-1086.
Monks, C. et al., “Three-dimensional segregation of supramolecular activation clusters in T cells,” Letters to Nature, Sep. 3, 1998, 395(6697), 82-86.
Montagna et al., Blood, 2000, vol. 96:175a, Poster Abstract #753.
Montagna, et al. 2001. Ex vivo priming for long-term maintenance of anitleukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood. vol. 98(12) pp. 3359-3366.
Moskophidis, D. et. al., “Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells,” Letters to Nature, Apr. 22, 1993, pp. 758-761.
Mulders, P. et al., 1999. Clin. Cancer Res. 3:445-454.
Richards, et al., “Therapeutic and Immunologic Evaluation of Autologous CTL Generated Using Transgenic Drosophila Cells as APC's for the Treatment of Melanoma,” Amer. Soc. Clin. Oncol. (Display: May 2001), 20(1of 2): Abstract 1015, p. 254a.
Riddell S.R. and P.D.Greenberg 1995 annual Review of Immunology 13:545-586.
Riddell S.R. and P.D.Greenberg 1994 Current Topics in Microbiology and Immunology 189:9-34.
Rosenberg, S.A. et al, N. Eng. J. Med. 1988 319:1676-1680.
Schultze, J.L. et al, Autologous tumor infiltrating Tcells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood May 1997, vol. 89, No. 10 pp. 3806-3816.
Sprent, et. al., “Constructing Artificial Antigen-Presenting Cells from Drosophilia Cells,” Advances in Exp. Medicine and Biology, 1997, 417, 249-254.
Sun et al., Dual Function of Drosophila Cells as APL for Naïve CD8+ T Cells: Implications for Tumor Immunotherapy, Immunity (1996) 4(6):555-564.
Sykulev et al., Proc. Natl. Acad. Sci., vol. 91, pp. 11487-11491, 1994.
Udaka et al., J. of Immunology, 1996, 157: 670-678.
Weber et
Cai Zeling
DeGraw Juli
Jackson Michael R.
Kong Yan
Peterson Per A.
Belyavskyi Michail A
Ortho-McNeil Pharmaceutical , Inc.
LandOfFree
Ex-vivo priming for generating cytotoxic T lymphocytes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ex-vivo priming for generating cytotoxic T lymphocytes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ex-vivo priming for generating cytotoxic T lymphocytes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230499